US Patent

US12201690 — Formulations/compositions comprising ibrutinib

Formulation · Assigned to Janssen Pharmaceutica NV · Expires 2039-06-14 · 13y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects formulations and compositions of ibrutinib, also known as Imbruvica, and methods for preparing and using them.

USPTO Abstract

Disclosed are formulations/compositions comprising ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

Drugs covered by this patent

Patent Metadata

Patent number
US12201690
Jurisdiction
US
Classification
Formulation
Expires
2039-06-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.